Articles

The week’s biggest announcement was WuXi AppTec’s sale of WuXi Advanced Therapies, its cell and gene therapy unit, to U.S.-based private equity firm Altaris.

The biopharmaceutical industry’s supply chain next year will again be strained. Here’s how the sector could build more resiliency.

As potentially curative therapies, CGTs offer hope to millions of patients but remain complex and difficult to manufacture at scale.

The acquisition, which took the global contract development and manufacturing organization private, is a one-off the likes of which the industry will not see again.

Though 2024 was a “mixed bag” for contract development and manufacturing organizations, a rosier picture is emerging for next year.

It may only be a matter of time until pharma companies will be able to defer to the technology for entire submissions creation

There remains huge untapped potential to increase efficiency in manufacturing and improve outcomes, and nowhere is that more pressing than for cell and gene therapies (CGTs). ...

The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.

From life-saving diabetes medications to essential respiratory treatments, several high-profile drugs will lose their patent exclusivity next year.

Drugmakers are tackling sustainability challenges to ensure energy efficiency and reduced environmental impact

This week, drug manufacturers — including Amgen, Eli Lilly, Novo Nordisk and Sanofi — announced plans to expand their production footprints in the U.S., Europe and Asia.

The future of non-clinical research may depend on integrating VCGs for a more humane and efficient approach.

A rundown of 2024’s defining pharma moments, from game-changing therapies to billion-dollar deals.

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of November 11

By embracing this standard, pharma facilities can create healthier, more sustainable buildings while contributing to a net-zero future

Here are the top things you need to know about the DSCSA, its implications, and how you can ensure your healthcare facility is compliant

How proactive maintenance safeguards quality, compliance, and reputation in pharmaceuticals.

This year’s Pharma Innovation Awards are setting new standards and quietly reshaping the future of pharma manufacturing

Despite notable progress in recent years, few organizations have fully leveraged a Pharma 4.0 strategy to its maximum potential.

How AI-inclusive advanced analytics platforms can enhance daily workflows by facilitating data collection, centralization and sharing

This year’s Pharma Innovation Awards are creating tools that elevate precision and efficiency in every step of the drug manufacturing process.

How making the most of your operations team can stabilize drug production

Building on its manufacturing legacy, Pittsburgh is now headed in a new direction — from steel to science

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 21

How to harness lab automation to create a seamless workflow and streamline drug testing processes.

The FDA recently granted exemptions from certain Drug Supply Chain Security Act (DSCSA) requirements to eligible trading partners facing challenges with data exchange. These exemptions...

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 14

With the annual global use of medicines predicted to reach $3.8 trillion defined daily doses by 20281, technology has a key role to play in helping pharma manufacturers ensure...

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 6

Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of September 30